SARS-CoV mAb shown to block SARS-CoV-2

By Samantha Black, PhD, The Science Advisory Board editor in chief

May 18, 2020 -- Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines, according to a new study. The findings were published in Nature on May 18.

Among the similarities of SARS-CoV from 2003 and the current pathogen, SARS-CoV-2, is the use of the functional receptor human angiotensin-converting enzyme 2 (ACE2) which binds with high affinity to the S domain subunit (receptor binding domain; RBD). Both coronaviruses belong to the sarbecovirus subgenus and their S proteins share 80% amino acid sequence identity.

Deactivating the S protein which mediates viral entry into host cells is the focus of many therapeutic and vaccine design efforts. Neutralizing antibodies, such as human monoclonal antibodies, can access S trimers, offering immediate protection against SARS-CoV-2 infection.

An international group of researchers had previously identified neutralizing monoclonal antibodies, taken from a patient who recovered from SARS in 2003, that potently inhibited both human and zoonotic SARS-CoV isolates. To investigate the potential cross-reactivity of the isolated monoclonal antibodies with SARS-CoV-2, in the current study the researchers performed memory B-cell screening using mononuclear cells collected in 2013 from the same patient. Out of the 25 monoclonal antibodies identified from the patient, eight were found to bind to SARS-CoV-2 RBD trimers.

Using a murine leukemia virus (MLV) pseudotyping system, the researchers identified one antibody, S309, which showed comparable neutralization potencies against both SARS-CoV and SARS-CoV-2 pseudoviruses and authentic isolates.

To understand the mechanism of neutralization, single-particle cyro-electron microscopy was used to characterize the complex between the S309 antigen binding fragment and a stabilized SARS-CoV-2 spike ectodomain trimer. From the crystal structure, the researchers found the domain formed an open and closed state, both with three S309 antigens bound. The antibody binds to a protein/glycan epitope on SARS-CoV-2 that is distinct from the receptor-binding motif in a conserved region.

From MLV analysis, the researchers determined that both S309 antigen fragments and immunoglobulin G (IgG) are capable of neutralizing SARS-CoV-2, indicating that one or more IgG-specific mechanisms such as S trimer cross-linking, steric hinderance, or aggregation of virions may contribute to neutralization. Moreover, they suggested that S309 could enhance the activation of natural killer cells and macrophages and contribute to antibody-dependent cell cytotoxicity and antibody-dependent cellular phagocytosis.

Together, their data indicate that S309 could neutralize essentially all SARS-CoV-2 isolates circulating to date and possibly many other zoonotic sarbecoviruses. The scientists also suggested that there may be a synergistic effect between two noncompeting anti-RBD monoclonal antibodies for SARS-CoV-2, although the current study was only a proof-of-concept examination and no human clinical trials have been conducted.

Do you have a unique perspective on your research related to virology or immunology? Contact the editor today to learn more.


Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
Bioinformatics helps pinpoint evolutionary mutations of SARS-CoV-2
A new bioinformatics approach to classifying genetic variants of SARS-CoV-2 helps to answer questions such as whether there are one or more circulating...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter